Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer

Table 2

Three-month baseline demographics and comorbidities of CAPN cases and non-CAPN controls.

	(A) Main Sample: no diabetes					(B) Diabetes Sample
	Cases		Controls		𝑃-value	Cases		Controls		𝑃-value^a
	No.	%	No.	%		No.	%	No.	%
𝑁	454		454			71		71
Demographics
Age (mean, SD)	53.9	7.5	53.7	9.3	0.0006	58.5	5.0	57.9	8.3	0.5044
Gender (𝑛, % male)	69	15%	69	15%	1.0000	13	18%	13	18%	1.0000
Employment Status (𝑛, % employed)	75	17%	75	17%	1.0000	3	4%	3	4%	1.0000
Months followup (mean)	11.1		2.2			11.3		1.7
12-month followup	366	81%				56	79%
Time to CAPN (mean days, SD)	147.5	82.9				137.2	85.7
1–3 months	125	27%				22	31%
3–6 months	149	33%				26	37%
6–9 months	179	39%				23	33%
Cancer type
Nonsmall cell lung	82	18%	82	18%	1.000	18	25%	18	25%	1.000
Breast	316	70%	316	70%	1.000	42	59%	42	59%	1.000
Ovarian	28	6%	28	6%	1.000	7	10%	7	10%	1.000
Head and neck	27	6%	27	6%	1.000	4	6%	4	6%	1.000
Metastatic cancer	168	37%	164	36%	0.7883	33	46%	20	28%	0.0374
Comorbidities
Depressive disorders	23	5%	31	7%	0.2673	2	3%	3	4%	0.6547
Congestive heart failure	20	4%	10	2%	0.0412	7	10%	8	11%	0.7963
Fibromyalgia	7	2%	7	2%	1.0000	4	6%	1	1%	0.1797
Obesity	8	2%	2	0%	0.0578	2	3%	0	0%	0.0578
Hypertension—uncomplicated	76	17%	52	11%	0.0164	22	31%	24	34%	0.7316
Hypertension—complicated	4	1%	13	3%	0.0290	4	6%	0	0%	0.0290
Other cancers	83	18%	74	16%	0.4352	17	24%	21	30%	0.4497
Charlson Comorbidity Index	4.4		4.3		0.4913	6.0		4.5		0.0043

CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation.
^a𝑃-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.